LEGN vs. CRSP

Last updated Jun 4, 2026

LEGN (Legend Biotech Corporation) and CRSP (CRISPR Therapeutics AG) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, LEGN returned -1.43%/yr vs -14.40%/yr for CRSP. At a 0.31 correlation, their price movements are largely independent.

Performance

LEGN vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Legend Biotech Corporation (LEGN) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LEGN achieves a 65.50% return, which is significantly higher than CRSP's -0.69% return.

LEGN

• 1D: -0.83%
• 1M: 35.77%
• YTD: 65.50%
• 6M: 29.66%
• 1Y: 26.56%
• 3Y*: -17.20%
• 5Y*: -1.43%
• 10Y*: —

CRSP

• 1D: 0.12%
• 1M: -2.80%
• YTD: -0.69%
• 6M: -6.98%
• 1Y: 36.91%
• 3Y*: -7.12%
• 5Y*: -14.40%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

LEGN vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
LEGN Legend Biotech Corporation	65.50%	-33.19%	-45.92%	20.53%	7.10%	65.52%	-23.89%
CRSP CRISPR Therapeutics AG	-0.69%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	145.92%

Correlation

The correlation between LEGN and CRSP is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.21
Correlation (3Y) Calculated over the trailing 3-year period	0.25
Correlation (5Y) Calculated over the trailing 5-year period	0.33
Correlation (All Time) Calculated using the full available price history since Jun 8, 2020	0.31

The correlation between LEGN and CRSP shifts across timeframes, from 0.21 (1 year) to 0.33 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap LEGN : $3.33B CRSP : $5.00B
EPS LEGN : -$1.55 CRSP : -$6.24
PS Ratio LEGN : 5.09 CRSP : 1.16K
PB Ratio LEGN : 3.44 CRSP : 2.76
Total Revenue (TTM) LEGN : $1.14B CRSP : $4.10M
Gross Profit (TTM) LEGN : $611.63M CRSP : -$171.17M
EBITDA (TTM) LEGN : -$186.04M CRSP : -$509.21M

Return for Risk

LEGN vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LEGN

LEGN Risk / Return Rank: 54
LEGN Sharpe Ratio Rank: 54
LEGN Sortino Ratio Rank: 62
LEGN Omega Ratio Rank: 58
LEGN Calmar Ratio Rank: 50
LEGN Martin Ratio Rank: 49

CRSP

CRSP Risk / Return Rank: 58
CRSP Sharpe Ratio Rank: 60
CRSP Sortino Ratio Rank: 60
CRSP Omega Ratio Rank: 56
CRSP Calmar Ratio Rank: 59
CRSP Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LEGN vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Legend Biotech Corporation (LEGN) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LEGN	CRSP	Difference
Sharpe ratio: Return per unit of total volatility	0.39	0.60	-0.21
Sortino ratio: Return per unit of downside risk	1.34	1.28	+0.06
Omega ratio: Gain probability vs. loss probability	1.15	1.15	0.00
Calmar ratio: Return relative to maximum drawdown	0.43	0.88	-0.45
Martin ratio: Return relative to average drawdown	0.67	1.49	-0.81
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LEGN vs. CRSP - Sharpe Ratio Comparison

The current LEGN Sharpe Ratio is 0.39, which is lower than the CRSP Sharpe Ratio of 0.60. The chart below compares the historical Sharpe Ratios of LEGN and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	LEGN	CRSP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.39	0.60	-0.21
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.03	-0.24	+0.21
Sharpe Ratio (All Time) Calculated using the full available price history	-0.01	0.23	-0.24

Drawdowns

LEGN vs. CRSP - Drawdown Comparison

The maximum LEGN drawdown since its inception was -78.24%, smaller than the maximum CRSP drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for LEGN and CRSP.

Drawdown Indicators

	LEGN	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-78.24%	-85.11%	+6.87%
Max Drawdown (1Y) Largest decline over 1 year	-62.43%	-42.25%	-20.18%
Max Drawdown (3Y) Largest decline over 3 years	-78.24%	-64.91%	-13.33%
Max Drawdown (5Y) Largest decline over 5 years	-78.24%	-80.68%	+2.44%
Current Drawdown Current decline from peak	-52.97%	-75.20%	+22.23%
Average Drawdown Average peak-to-trough decline	-31.34%	-49.17%	+17.83%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.47%	24.92%	+14.55%

Volatility

LEGN vs. CRSP - Volatility Comparison

Legend Biotech Corporation (LEGN) has a higher volatility of 40.69% compared to CRISPR Therapeutics AG (CRSP) at 14.90%. This indicates that LEGN's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LEGN	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	40.69%	14.90%	+25.79%
Volatility (6M) Calculated over the trailing 6-month period	57.77%	42.49%	+15.28%
Volatility (1Y) Calculated over the trailing 1-year period	69.00%	61.68%	+7.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	56.04%	60.46%	-4.42%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	55.65%	64.27%	-8.62%

Dividends

LEGN vs. CRSP - Dividend Comparison

Neither LEGN nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both LEGN and CRSP in my portfolio?

LEGN and CRSP have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, LEGN or CRSP?

LEGN has higher volatility (40.69%) compared to CRSP (14.90%). In terms of maximum drawdown, LEGN dropped -78.24% vs CRSP's -85.11%.

Which has better risk-adjusted returns?

CRSP currently has the higher Sharpe Ratio (0.60 vs 0.39), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.